Key result
The Aeson bioprosthetic total artificial heart successfully bridged a 58-year-old man with a severe post-infarction ventricular septal defect to heart transplantation after 26 days of support.
Why the study?
Post-infarction ventricular septal defects have high mortality rates, and surgical or interventional treatments are sometimes technically unfeasible and do not always ensure good outcomes.
Does the Aeson bioprosthetic total artificial heart allow safe bridging to transplantation in a patient with post-infarction ventricular septal rupture and cardiogenic shock?
Case Report (n=1)
No
Does the Aeson bioprosthetic total artificial heart allow safe bridging to transplantation in a patient with post-infarction ventricular septal rupture and cardiogenic shock?
The Aeson bioprosthetic total artificial heart can serve as a successful bridge to transplantation in patients with complex post-infarction ventricular septal defects unsuitable for conventional surgery or interventional therapy.
Authors
No takes yet. Share an insight, caveat, or question.
May extend TAH options to post-MI VSD; hypothesis-generating without altering practice.
Huenges et al. (2023) conducted a case report in Post-infarction ventricular septal rupture (n=1). Aeson bioprosthetic total artificial heart (CARMAT) was evaluated on Successful bridge to heart transplantation. The Aeson bioprosthetic total artificial heart successfully bridged a 58-year-old man with a severe post-infarction ventricular septal defect to heart transplantation after 26 days of support.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: